Off-Label Use of Atypical Antipsychotics: An Update
Results and Summary of Benefits: Atypical Antipsychotics for Bipolar Personality Disorder
Of seven studies of bipolar personality disorder (BPD), four showed statistically significant beneficial effects. Two studies showed some efficacy of aripiprazole, but the strength of evidence is low. One study showed that olanzapine is efficacious at 5–10 mg/day but not at 2.5 mg/day. The strength of evidence for the finding is low.
In summary, although there is some evidence for benefit from atypical antipsychotics for BPD, it is inadequate for a meta-analysis and conclusions about the statistical or clinical significance of the effect.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | borderline personality | BPD | aripiprazole | olanzapine | quetiapine
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.